Trial
NCT03490942
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Xeris Pharmaceuticals
Collaborators
Integrated Medical Development
Condition
Hypoglycemia Unawareness
Intervention
Glucagon
Why stopped
Primary endpoint was not met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-21